Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,836 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07670286Recruiting
Spotting early warning signs of pancreatic cancer wasting
This study checks if advanced computer analysis of your tumor and body can predict severe weight loss and muscle wasting (cachexia) from pancreatic cancer. If you join, you may help doctors find earlier warning signs to improve treatment.
BeijingAges 18 years+ - NCT07671339RecruitingPhase 1
Vaccine for pancreatic cancer with KRAS mutations
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
Basking Ridge, New JerseyAges 18 years+ - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07656116RecruitingPhase 1
Oncolytic virus therapy for advanced solid tumors
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
Langfang, HebeiAges 18 years+ - NCT06411600RecruitingPhase 2
Combination therapy for BRAF-mutated colorectal cancer
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
BarcelonaAges 18 years+ - NCT07648472RecruitingPhase 1
Safety and efficacy of OVV-01 injection for advanced solid tumors
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07643623RecruitingPhase 2/Phase 3
Immunotherapy for operable stomach cancer before and after surgery
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07644039RecruitingPhase 1/Phase 2
PM54 plus immunotherapy for advanced cancer
This study tests a new drug called PM54 combined with pembrolizumab (an immunotherapy) in people with advanced cancers that have gotten worse despite prior treatment. The goal is to see if this combination can slow or stop cancer growth.
New York, New YorkAges 18 years+ - NCT07639450RecruitingPhase 1/Phase 2
N-3C01 Cancer Treatment Study for Advanced Solid Tumors
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
Saint Leonards, New South WalesAges 18–75 - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT06639347RecruitingPhase 1/Phase 2
Testing SHR-A2102 for advanced bladder cancer
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Guangzhou, GuangdongAges 18 years+ - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT07636148Recruiting
Registry of minimally invasive cancer treatment with advanced imaging
This study collects information from patients undergoing minimally invasive procedures to treat solid tumors (cancers) using advanced CT imaging guidance. Researchers want to understand how well this imaging technique helps doctors perform these procedures safely and effectively.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07636200Recruiting
Managing Fear and Worry in Advanced Cancer
This study tests a new approach to help people with advanced cancer who feel significant fear about their cancer getting worse or coming back. The program uses writing and therapeutic techniques to help reduce this fear and related stress.
Aurora, ColoradoAges 18 years+ - NCT07634380RecruitingPhase 1
Sitagliptin Plus Pembrolizumab for Advanced Kidney or Skin Cancer
This study tests whether adding sitagliptin (a diabetes medication) to pembrolizumab (an immunotherapy) can help patients with advanced kidney cancer or melanoma whose cancer stopped responding to previous immunotherapy treatments. The goal is to see if this combination can shrink tumors and improve survival.
Iowa City, IowaAges 18–99 - NCT07623174Recruiting
Fruquintinib for Advanced Colorectal Cancer in Poland
This study follows adults in Poland who are receiving fruquintinib, a targeted cancer medicine, for advanced colorectal cancer that has spread. You would be enrolled if your doctor is already planning to give you fruquintinib as a later-line treatment after other therapies have stopped working.
Poznan, Greater Poland VoivodeshipAges 18 years+ - NCT07629258RecruitingPhase 1
Testing GW01-200 tablets in advanced cancer patients
This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT06601283RecruitingPhase 2/Phase 3
Vitamin C and Cordyceps for Anemia in Pancreatic Cancer
This trial tests whether adding vitamin C and a fungus called cordyceps to standard chemotherapy can help improve anemia (low red blood cells) in people with advanced pancreatic cancer. It's for those who have not yet had treatment for their cancer.
ShanghaiAges 18–80 - NCT06598033RecruitingPhase 2/Phase 3
Vitamin C and Cordyceps for quality of life in advanced pancreatic cancer
This trial tests whether a combination of high-dose vitamin C and cordyceps (a type of fungus used in traditional medicine) can improve quality of life for people with late-stage pancreatic cancer that has progressed after two prior treatments. It looks at how these supplements affect your well-being and daily living.
ShanghaiAges 18–80 - NCT07617610Recruiting
Understanding Treatment Resistance in BRAF-Mutated Colorectal Cancer
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
AarauAges 18 years+ - NCT07617493RecruitingPhase 1/Phase 2
ICP-B208 for Advanced Solid Tumors
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
Beijing, Beijing MunicipalityAges 18–75 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,836 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.